Key result
Alstonia scholaris alkaloids cut triglycerides ~40% and alleviate hepatic steatosis in high-fat diet mice.
Why the study?
Alstonia scholaris is traditionally documented for treating liver diseases, but its effects on nonalcoholic fatty liver disease required investigation.
Do indole alkaloids of Alstonia scholaris (TA) alleviate non-alcoholic fatty liver disease in mice fed a high-fat diet?
Do indole alkaloids of Alstonia scholaris (TA) alleviate non-alcoholic fatty liver disease in mice fed a high-fat diet?
Absolute Event Rate: 133.5% vs 222.2%
p-value: p=<0.01
Indole alkaloids of Alstonia scholaris attenuate NAFLD in mice by regulating hepatic lipogenesis and fatty acid oxidation.
Alstonia scholaris (L.) R. Br (Apocynaceae) is a well-documented medicinal plant for treating respiratory diseases, liver diseases and diabetes traditionally. The current study aimed to investigate the effects of TA on non-alcoholic fatty liver disease (NAFLD). A NAFLD model was established using mice fed a high-fat diet (HFD) and administered with TA (7.5, 15 and 30 mg/kg) orally for 6 weeks. The biochemical parameters, expressions of lipid metabolism-related genes or proteins were analyzed. Furthermore, histopathological examinations were evaluated with Hematoxylin-Eosin and MASSON staining. TA treatment significantly decreased the bodyweight of HFD mice. The concentrations of low-density lipoprotein (LDL), triglyceride (TG), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were also decreased significantly in TA-treated mice group, accompanied by an increase in high-density lipoprotein (HDL). Furthermore, TA alleviated hepatic steatosis injury and lipid droplet accumulation of liver tissues. The liver mRNA levels involved in hepatic lipid synthesis such as sterol regulatory element-binding protein 1C (SREBP-1C), regulators of liver X receptor α (LXRα), peroxisome proliferator activated receptor (PPAR)γ, acetyl-CoA carboxylase (ACC1) and stearyl coenzyme A dehydrogenase-1 (SCD1), were markedly decreased, while the expressions involved in the regulation of fatty acid oxidation, PPARα, carnitine palmitoyl transterase 1 (CPT1A), and acyl coenzyme A oxidase 1 (ACOX1) were increased in TA-treated mice. TA might attenuate NAFLD by regulating hepatic lipogenesis and fatty acid oxidation.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) studied Non-alcoholic fatty liver disease (NAFLD) (n=50). Total alkaloids of Alstonia scholaris vs. High-fat diet alone was evaluated on Plasma triglyceride (TG) levels (μg/mL) (p=<0.01). Total alkaloids of Alstonia scholaris at 30 mg/kg significantly reduced plasma triglyceride levels and alleviated hepatic steatosis in mice fed a high-fat diet.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: